NVO – Novo Nordisk A/S
Novo Nordisk A/SNVO
$62.55Name : Novo Nordisk A/S
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $276,265,205,760.00
EPSttm : 3.27
Novo Nordisk A/S
$62.55
6.78%$4.55Float Short %
0.38
Margin Of Safety %
47
Put/Call OI Ratio
0.85
EPS Next Q Diff
5.04
EPS Last/This Y
EPS This/Next Y
5.09
Price
62.54
Target Price
114.15
Analyst Recom
1.86
Performance Q
-28.53
Relative Volume
1.26
Beta
0.65
Ticker: NVO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | NVO | 90.83 | 0.69 | 0.41 | 380229 |
| 2025-03-06 | NVO | 88.01 | 0.70 | 1.18 | 385029 |
| 2025-03-07 | NVO | 87.17 | 0.71 | 0.62 | 392717 |
| 2025-03-10 | NVO | 78.94 | 0.64 | 0.93 | 370814 |
| 2025-03-11 | NVO | 78.09 | 0.67 | 0.77 | 399419 |
| 2025-03-12 | NVO | 74.78 | 0.67 | 0.67 | 413708 |
| 2025-03-13 | NVO | 75.93 | 0.68 | 1.35 | 426963 |
| 2025-03-14 | NVO | 77.16 | 0.69 | 1.55 | 435768 |
| 2025-03-17 | NVO | 80.15 | 0.70 | 0.88 | 430401 |
| 2025-03-18 | NVO | 80.99 | 0.70 | 0.60 | 440052 |
| 2025-03-19 | NVO | 79.02 | 0.70 | 0.85 | 444215 |
| 2025-03-20 | NVO | 78.79 | 0.70 | 1.17 | 453327 |
| 2025-03-21 | NVO | 76.86 | 0.71 | 1.21 | 460465 |
| 2025-03-24 | NVO | 75.31 | 0.79 | 1.12 | 380380 |
| 2025-03-25 | NVO | 73.57 | 0.81 | 1.41 | 404898 |
| 2025-03-26 | NVO | 71.71 | 0.89 | 0.82 | 440176 |
| 2025-03-27 | NVO | 70.17 | 0.89 | 2.32 | 464962 |
| 2025-03-28 | NVO | 69.28 | 0.92 | 1.63 | 490616 |
| 2025-03-31 | NVO | 69.47 | 0.94 | 0.83 | 465169 |
| 2025-04-01 | NVO | 68.06 | 0.88 | 0.76 | 462879 |
| 2025-04-02 | NVO | 68.33 | 0.86 | 0.66 | 470700 |
| 2025-04-03 | NVO | 67.12 | 0.86 | 1.40 | 477035 |
| 2025-04-04 | NVO | 62.54 | 0.85 | 1.46 | 475949 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | NVO | 90.83 | 10.3 | 5712.6 | 27.40 |
| 2025-03-06 | NVO | 88.05 | 10.3 | 5128.4 | 27.40 |
| 2025-03-07 | NVO | 87.18 | 10.3 | 5597.1 | 27.36 |
| 2025-03-10 | NVO | 78.96 | 10.3 | 3961.4 | 27.36 |
| 2025-03-11 | NVO | 78.11 | 10.3 | 5567.4 | 27.36 |
| 2025-03-12 | NVO | 74.77 | 10.3 | 4597.7 | 27.36 |
| 2025-03-13 | NVO | 75.89 | 10.3 | 5707.5 | 27.36 |
| 2025-03-14 | NVO | 77.15 | 10.3 | 7129.1 | 27.36 |
| 2025-03-17 | NVO | 80.15 | 10.3 | 7238.8 | 27.36 |
| 2025-03-18 | NVO | 80.98 | 10.2 | 7250.0 | 27.36 |
| 2025-03-19 | NVO | 79.00 | 10.2 | 6013.5 | 27.36 |
| 2025-03-20 | NVO | 78.79 | 10.2 | 5905.7 | 27.36 |
| 2025-03-21 | NVO | 76.89 | 10.2 | 5350.7 | 27.36 |
| 2025-03-24 | NVO | 75.33 | 10.3 | 4976.1 | 27.36 |
| 2025-03-25 | NVO | 73.60 | 10.3 | 5101.6 | 27.36 |
| 2025-03-26 | NVO | 71.73 | 10.3 | 4832.5 | 27.20 |
| 2025-03-27 | NVO | 70.14 | 10.3 | 4736.1 | 27.20 |
| 2025-03-28 | NVO | 69.30 | 10.3 | 5018.5 | 27.20 |
| 2025-03-31 | NVO | 69.44 | 10.2 | 6637.3 | 27.22 |
| 2025-04-01 | NVO | 68.03 | 8.1 | 6366.6 | 26.88 |
| 2025-04-02 | NVO | 68.24 | 8.1 | 5989.0 | 26.88 |
| 2025-04-03 | NVO | 67.10 | 8.1 | 6186.2 | 26.88 |
| 2025-04-04 | NVO | 62.54 | 7.2 | 4188.0 | 26.71 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | NVO | 0.00 | 0.19 | 0.40 |
| 2025-03-06 | NVO | 0.00 | 0.19 | 0.40 |
| 2025-03-07 | NVO | 0.00 | 0.19 | 0.40 |
| 2025-03-10 | NVO | 0.00 | 0.17 | 0.40 |
| 2025-03-11 | NVO | 0.00 | 0.17 | 0.40 |
| 2025-03-12 | NVO | 0.00 | 0.17 | 0.40 |
| 2025-03-13 | NVO | 0.00 | 0.17 | 0.40 |
| 2025-03-14 | NVO | 0.00 | 0.17 | 0.40 |
| 2025-03-17 | NVO | 0.00 | 0.02 | 0.40 |
| 2025-03-18 | NVO | 0.00 | 0.02 | 0.40 |
| 2025-03-19 | NVO | 0.00 | 0.02 | 0.40 |
| 2025-03-20 | NVO | 0.00 | 0.02 | 0.40 |
| 2025-03-21 | NVO | 0.00 | 0.02 | 0.40 |
| 2025-03-24 | NVO | 0.00 | 0.32 | 0.40 |
| 2025-03-25 | NVO | 0.00 | 0.32 | 0.40 |
| 2025-03-26 | NVO | 0.00 | 0.32 | 0.38 |
| 2025-03-27 | NVO | 0.00 | 0.32 | 0.38 |
| 2025-03-28 | NVO | 0.00 | 0.32 | 0.38 |
| 2025-03-31 | NVO | 0.00 | -0.91 | 0.38 |
| 2025-04-01 | NVO | 0.00 | -0.91 | 0.38 |
| 2025-04-02 | NVO | 0.00 | -0.91 | 0.38 |
| 2025-04-03 | NVO | 0.00 | -0.91 | 0.38 |
| 2025-04-04 | NVO | 0.00 | -0.91 | 0.38 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.91
Avg. EPS Est. Current Quarter
6.14
Avg. EPS Est. Next Quarter
5.95
Insider Transactions
Institutional Transactions
-0.91
Beta
0.65
Average Sales Estimate Current Quarter
79034
Average Sales Estimate Next Quarter
81866
Fair Value
91.79
Quality Score
99
Growth Score
99
Sentiment Score
46
Actual DrawDown %
57.8
Max Drawdown 5-Year %
-54.3
Target Price
114.15
P/E
19.06
Forward P/E
13.06
PEG
0.96
P/S
5
P/B
13.94
P/Free Cash Flow
19.66
EPS
3.28
Average EPS Est. Cur. Y
26.71
EPS Next Y. (Est.)
31.8
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
34.81
Relative Volume
1.26
Return on Equity vs Sector %
50.6
Return on Equity vs Industry %
43.6
EPS 1 7Days Diff
26.7
EPS 1 30Days Diff
26.71
EBIT Estimation
4188
Novo Nordisk A/SSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 76302
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
stock quote shares NVO – Novo Nordisk A/S Stock Price stock today
news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch NVO – Novo Nordisk A/S yahoo finance google finance
stock history NVO – Novo Nordisk A/S invest stock market
stock prices NVO premarket after hours
ticker NVO fair value insiders trading